Molecular drivers of pediatric PTC mostly comprise gene fusions involving RET, NTRK1, and NTRK3 [3, 4], with TRK fusions identified in about 25% of patients at a tertiary cancer center who develop distantly metastatic disease [2]. Here, NTRK1 is linked to metastatic neoplasm.